MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14712598.2026.2635517

Медицинская библиотека · Expert opinion on biological therapy · 2026

Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials.

Di Lernia Vito, Sticchi Alberto

СтатьяОбзорПеревод в очереди

Аннотация

Background

Prurigo nodularis (PN) is a chronic, debilitating neuro-immunological skin disease characterized by intense pruritus and hyperkeratotic nodules. Nemolizumab, a novel IL-31 receptor alpha antagonist targeting the neural itch pathway, was investigated in PN.Areas covered: Two randomized phase 3 studies, the Olympia 1 and Olympia 2 trials, provided favorable efficacy and safety data for nemolizumab versus placebo in moderate-to-severe PN. After 16 weeks, a ≥4-point reduction in PP-NRS was achieved in 58.4% (Olympia 1) and 56.3% (Olympia 2) of nemolizumab patients compared to 16.7% and 20.9% in placebo groups, respectively (p<0.001). Safety data showed no drug-related serious adverse events or organ toxicity.Expert opinion: These trials were the first to clinically demonstrate IL-31 inhibition in PN. Nemolizumab represents a paradigm shift in PN therapy, acting as a potent "neuro-modulator" with rapid itch relief, often observed by Week 4.

Conclusions

Future management may rely on disease endotypes to select between neural (IL-31) and immune (IL-4/13) blockade.

Для цитирования: Di Lernia Vito, Sticchi Alberto. Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials.. Expert opinion on biological therapy. 2026. DOI: 10.1080/14712598.2026.2635517.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.